Iceland vs Norway: Hepatitis B surface antigen (HBsAg) prevalence
Iceland
0.0%
in 2024
Norway
0.0%
in 2024
Iceland rank
132nd
Norway rank
132nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Iceland
- Norway
How they compare
Iceland currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
Iceland ranks 132nd and Norway ranks 132nd of 194 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Iceland | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Iceland or Norway?
- Iceland, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Iceland and Norway?
- 0.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do Iceland and Norway rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Iceland ranks 132nd and Norway ranks 132nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.